Results 111 to 120 of about 56,758 (258)
ABSTRACT Pediatric supportive care clinical trials often involve multiple clinically important outcomes, complicating trial interpretation. Hierarchical composite endpoints (HCEs) provide a framework to integrate key outcomes according to clinical importance.
Willem H. Collier +11 more
wiley +1 more source
ABSTRACT Background Childhood aplastic anemia (AA) is a rare disease, and both the disease itself and its treatment cause significant morbidity. We aimed to determine the contemporary incidence of childhood AA in Finland, to compare the clinical characteristics of AA against inherited bone marrow failure syndromes (IBMFS) and refractory cytopenia of ...
Lauri‐Matti Kulmala +8 more
wiley +1 more source
The Role of Chemotherapy in Pediatric Myoepithelial Carcinoma: A Systematic Review of the Literature
ABSTRACT Myoepithelial carcinoma (MEC) in pediatric patients is a rare and aggressive malignancy characterized by heterogeneous morphology and variable molecular features. The optimal role of chemotherapy remains unclear. We conducted a systematic review according to PRISMA 2020 guidelines to evaluate chemotherapy in pediatric and young‐adult patients ...
Marco Salvi +7 more
wiley +1 more source
Determining Parental Factors for Clinical Trial Attrition in Pediatric Acute Lymphoblastic Leukemia
ABSTRACT Background/Objectives Despite high enrollment rates on Children's Oncology Group (COG) protocols, attrition after initial consent is challenging, introducing bias and prolonging trial completion. While adult oncology literature has identified predictors of withdrawal, little is known about caregiver decision‐making for child participation in ...
Kimberly L. Stathas +3 more
wiley +1 more source
Advancing In Vitro Tools for Oncologic Research in Cats and Dogs
In vitro culture systems have advanced cancer biology, particularly through 2D and 3D tumor cultures. These have answered numerous scientific inquiries and propelled human oncologic research, with growing recognition of their potential to improve cancer ...
Chang He, Sven Rottenberg
doaj +1 more source
ABSTRACT Blinatumomab, a CD19xCD3 bispecific T‐cell engager, has become standard therapy for children with de novo B‐cell acute lymphoblastic leukemia (B‐ALL). This retrospective review describes the experience of blinatumomab administration in pediatric patients.
Julia M. Hurley +6 more
wiley +1 more source
Flexibility in noisy cell-to-cell information dynamics
The exchange of molecules allows cells to exchange information. How robust is the information to changes in cell parameters? We use a mapping between the stochastic dynamics of two cells sharing a stimulatory molecule and parameters akin to an extension ...
Ismail Qunbar +2 more
doaj +1 more source
DRG2 as a Biomarker to Enhance the Predictive Efficacy of PD-L1 Immunohistochemistry Assays
PD-L1 immunohistochemistry (IHC) assays are used as a companion diagnostic for immunotherapy with immune checkpoint inhibitors (ICIs). However, despite the association between PD-L1 expression and clinical benefit from ICIs, the PD-L1 IHC assay is not ...
Muralidharan Mani +3 more
doaj +1 more source
ABSTRACT We report a retrospective single‐center analysis of pediatric patients with relapsed or refractory B‐cell precursor acute lymphoblastic leukemia focusing on relapses outside of the typical locations, bone marrow, central nervous system, or testes.
Johanna Kunz +7 more
wiley +1 more source
ABSTRACT Background Together, leukemia and lymphoma account for 38.7% of newly diagnosed pediatric cancer cases in the United States each year. Many caregivers utilize online resources to inform medical health decisions. Understanding the readability of these materials is critical to ensuring comprehensible patient education.
Chloe Strege +6 more
wiley +1 more source

